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In the wake of dynamic economic and political transitions worldwide, the Institute of Medicine recently
released its report advocating investments in global health from the United States (US). The expert panel
reinforces the ‘transnational and interdisciplinary’ nature of global health research and practice as an
endeavor ‘to improve health and achieve greater equity for all people worldwide.’ This report was judiciously
timed given the growing recognition of global health, and is also acknowledged for incorporating themes that
are particularly pertinent to the twenty-first century. New paradigms are introduced, denouncing the
dichotomous distinction between rich and poor countries with the rapidly transitioning countries emerging as
global powers, and affirming the need for models of respectful partnership and wider translation of science
into practice. Cultivating sustainable partnerships and investing in the understanding and combat of diseases
worldwide will become increasingly important for the US to maintain its global competitiveness, and may
offer lessons in innovation, efficiency, and organization of institutions and human resources.
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I
n his recent speech at Cairo University on the 4th of
June 2009, President Obama eloquently spoke of a
rapidly globalizing world, ‘... when a financial system
weakens in one country, prosperity is hurt everywhere.
When a new flu infects one human being, all are at risk.
When one nation pursues a nuclear weapon, the risk of
nuclear attack rises for all nations. When violent ex-
tremists operate in one stretch of mountains, people are
endangered across an ocean. And when innocents in
Bosnia and Darfur are slaughtered, that is a stain on our
collective conscience. That is what it means to share this
world in the 21st century. That is the responsibility we
have to one another as human beings. This is a difficult
responsibility to embrace.’ (1)
In line with this growing realization of contemporary
global inter-dependence, the Institute of Medicine’s
(IOM) recent report entitled ‘The U.S. Commitment to
Global Health: Recommendations for the Public and
Private Sectors’
1 is particularly timely (2). This report
was the product of an expert committee, chaired by
Harold Varmus, Nobel Laureate and former director of
the United States (US) National Institutes of Health
(NIH), and is an updated collection of recommendations,
building on several influential organizations and texts
that embody this theme (35). Global health engenders
issues that transcend national boundaries, and requires
global cooperation, multi-disciplinary, and interdisciplin-
ary involvement toward achieving greater socioeconomic
and health equity, for both domestic and international
populations (6).
The committee articulates a clear rationale for invest-
ment by the US governmental and non-governmental
organizations (universities, civil society, relief organiza-
tions, and other private ventures) in global health
research and initiatives. The imperative is based on the
unique current opportunity (given passionate interest and
financial commitments from a wide range of vested
groups) as well as acknowledgements of global inter-
dependence in health and the significance of poverty
reduction and socioeconomic development for sustain-
able health gains everywhere. The report graciously
declares that this is neither an exclusive venture to be
taken up by the US, nor is it solely the responsibility of
health sector affiliates, but rather requires respectful and
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by way of imparting financial commitment and technical
skill.
The recommendations
The five groups of recommendations set forth by the
committee are specific and comprehensive, and are
followed by a ‘call to action’ encouraging sustainable
investment and coordination of vested groups.
Scaling up existing interventions
The report highlights the gap between current evidence
supporting cost-effective health interventions, and low
levels of implementation of these proven tools and
technologies. There is also an emphasis on building
and/or strengthening health systems toward more evi-
dence-based and integrated health care delivery. The
authors note the constraints of financing, infrastructure,
and trained personnel, but also stress the fundamental
role of favorable policy frameworks, capacity-building,
and institutional development.
Generate and share knowledge endemic to the
global poor
The report acknowledges the US’ contribution to science,
but appropriately criticizes the focus on investigating a
narrow range of diseases that affect developed countries.
Research funds tend to be disproportionately skewed
toward high-profile diseases, while suboptimal distribution
of proven technologies and interventions for under-nutrition,
vaccine-preventable diseases, and non-communicable
diseases (NCD) (7) receive little attention, thereby
perpetuating the mortality and morbidity burdens due
to these conditions. Furthermore, current contributions
toward multi-lateral organizations (e.g. the Global Fund
to Fight AIDS, TB, and Malaria) have not been
optimized. In the case of TB, for example, antiquated
diagnostic tools and therapeutic options dating back at
least a half-century are still the mainstays used today,
perpetuating the development of drug resistance. As
such, the report emphasizes the significance of: appro-
priate application of innovation and technology toward
identifying acceptable and accessible solutions; health
systems research; novel proliferation incentives (e.g.
advanced market commitments); and improved methods,
greater connectivity, and wider access for disseminating
knowledge to contexts where they are most urgently
required, especially since good health outcomes result
from applying global strategies through local forces
(communities, families, and decentralized institutions).
Investing in people, institutions, and capacity-
building
Local resources are critical to the execution and con-
tinuity of health initiatives. Also, as a matter of global
responsibility, the US should invest in health worldwide
as it has and continues to rely heavily on internationally
trained health workers; in the year 2000, foreign-trained
nurses and physicians accounted for 9.1 and 25% (a
combined workforce totaling over 350,000 professionals)
of US health personnel, respectively (8, 9). Acknowl-
edging the need for skilled, experienced, and knowledge-
able health professionals to remain vested in low and
middle-income countries (LMIC), the recommendations
outline incentives (monetary, career-enhancing opportu-
nities), and leveraging scientific and academic collabora-
tions toward skills transfer, policy development, and
improving institutional capacity. The National Heart
Lung and Blood Institute’s (NHLBI) recent Global
Health Initiative (10, 11) provides a good example of
advancing research and human resource development in
LMICs through financing institutional partnerships for
chronic diseases research. This scheme and the Fogarty
International Scholars Program incorporate opportu-
nities for US investigators and trainees to work in new
and varied environments, and forges alliances with US
universities. In the long term, imparting models that
engender high-quality scientific investigation and self-
sufficiency will augment coordinated research and health
programs between countries, inform national policies,
and also create opportunities for young analysts, re-
searchers, and junior faculty to be able to remain in-
country and complete the circle by teaching others. Local
capability will breed sustainability and foster global
collaboration.
Increase financial commitments
While the Obama administration has pledged US$13
billion annually to global health initiatives up to 2014, the
IOM report urges that current commitments overlook the
burden of NCDs. Although not included in the UN
Millennium Development Goals, these diseases account
for 60% of mortality worldwide, of which 80% occurs in
LMICs, affecting young and vulnerable subpopulations,
often with devastating societal and individual socio-
economic impacts (12). Augmented investments in global
health must be comprehensive, continuing to support
initiatives aimed at highly prevalent infectious threats,
but also providing funds for neglected diseases of poverty
and health systems development. Novel transaction
mechanisms and training methods can aid local dissemi-
nation of financing, procurement and distribution of
diagnostics, therapeutics, and vaccines, and capacity
development; ultimately, it is the local institutions
(families, communities, and service organizations) that
can best adapt global solutions to local contexts in order
to deliver sustainable results. At the same time, concerted
global cooperation among leaders of nations is required
to address broader issues like global warming and its
effects on health.
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Truly valuable capacity-building should avoid simple
paternalistic models of aid and skills transfer. Effective
leadership by example and recognition of the complex-
ities of engaging partners globally are key tenets in the
process. Conveying organizational tools (structures, pro-
cesses, and outcomes) and strengthening the health and
public policy research and implementation workforce
increases self-assurance and accountability of these
sectors in LMICs. In addition, the report advocates
coordination amongst the huge variety of agencies
involved in global health. Although the recommendation
is justified and current efforts are fragmented, sometimes
duplicated, and often unplanned and improvized, it must
be acknowledged that coordinating this plethora of
vested groups introduces immense complexity and tradi-
tional models of organizing and synchronizing efforts
may not work. The recently formed Global Alliance for
Chronic Diseases, a consortium of six of the world’s most
influential health agencies, is a promising new venture
committed to coordinating the global health community’s
fight against NCDs, and will attempt to do so by
engaging more collaborative priority-setting (13).
Commentary
We would add that investing in global health is not
wholly an altruistic goal, and need not be; but will also
benefit the US through curbing the risk of communicable
health threats, enhancing research collaborations and
increasing innovation possibilities, offering opportunities
for American academics and organizations, improving
the global image of the US, promoting strategic align-
ments, and encouraging greater cooperation and trade
with countries with increasing economic and political
influence. Examples of this reasoning follow.
With increasing migration, travel, and human displace-
ment, communicable agents threaten the health of all
populations. For example, in 2004, there were 338 million
border entries and exits documented in the US, a 5%
increase from the previous year (14), and in 2007, there
were 13,000 reported cases of TB in the US (15). Recent
developments and the rapid spread of infectious agents
like the Severe Acute Respiratory Syndrome (SARS) and
H1N1 influenza virus, along with the growth of drug
resistant infections worldwide, exemplify the reasons
reinforcing global cooperation in surveillance and disease
control.
Collaborative investigation of patho-physiological me-
chanisms and disease interventions can promote health
globally while benefiting the increasingly multiethnic
population of the US, and inform long-awaited health
system reforms. Nabel et al. (11) describe how ‘rigorous
research undertaken at diverse sites will also enrich our
basic understanding of disease causation and of the
interplay between biological, environmental, and socio-
cultural contributors to public health.’ Additionally,
research to test the effectiveness and cost-effectiveness
of practical, low-cost interventions in real-life settings
where suboptimal circumstances are common, satisfies
many of the themes stipulated in the report and offers the
potential of scalability and sustainability. Arguably, out
of necessity, there is a high tolerance for risk in the types
of innovative research undertaken in resource constrained
settings of LMICs. For example, the Bill and Melinda
Gates Foundation sponsored a study in rural India from
which a cervical cancer screening test emerged as effective
and acceptable, prompting the likelihood that this test
will replace long-established pap smears (16, 17).
Furthermore, the manufacturers of the test have declared
that market demand and Gates Foundation subsidies will
lower the cost to approximately US$5 per test, making it
a viable option for rich and poor countries alike.
Global partnerships may also encourage rapid and
cost-effective scientific innovation and discoveries. For
instance, although the promise of a polypill for preven-
tion of cardiovascular disease events has been around for
some years (18, 19), there has been little progress in this
direction in developed countries. However, recognizing
the looming health and economic threat of NCDs,
researchers in India collaborated with investigators in
Canada to investigate the viability of this simple, low-cost
idea. The Indian Polycap phase II study (20) is thus an
example of a trial with potentially significant global
impacts that overcame scientific and political barriers.
The success of the polypill is likely to have impacts on
lowering costs, enhancing adherence, expanding accessi-
bility, and improving multiple risk factor control in both
LMICs and more developed countries (21). Another
noteworthy alliance between GlaxoSmithKline and Dr.
Reddy’s Laboratories, a large India-based manufacturer,
to promote the development and marketing of generic
drugs to LMICs, highlights the growing need for low-cost
drugs for the majority of the world’s population (22).
There may also be lessons for the US health system
from comparative cost-effectiveness analyses of different
models of delivery and health technology utilization. For
instance, private health care providers and insurance
companies in India are increasingly catering to a large
market of people in lower socioeconomic strata (23). The
Aravind Eye Hospitals (AEH) have become a renowned
example, operating a high-volume, low-cost model of
delivery where 285,000 eye operations are performed
annually, and the tiered fee system results in almost 65%
of these being provided at no cost to those in need. In
making sensible decisions regarding resource allocation,
independent evidence-based recommendations to govern-
ment to regulate the use of health technologies, as is the
function of the National Institutes of Clinical Excellence
The United States and global health
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told, no single strategy would be infallible, but learning
from a variety of contexts and applying a combination of
strategies may help reduce expenditures and create a
more sustainable US health system.
Industries that supply diagnostic, therapeutic, and
preventative tools and technologies may also benefit
from international collaborations. More rapid and cost-
effective scientific discovery as well as creativity and
innovation are key components of competitive advantage
in a globalized world. Currently, research and develop-
ment costs average US$800 million per new drug in the
US and require eight years from clinical testing to
marketing (24). In comparison to SmithKline Beecham’s
price of US$20 per shot of Hepatitis B vaccine, a vaccine
research firm in India employs innovative and efficient
processes to deliver the same product for 28 cents (25).
The AEH, cited above, similarly manufactures high-
quality intra-ocular lenses at a cost of US$5, compared
to the US $80100 when imported, and has supplied more
than 2 million lenses to over 85 countries (26). Innovation,
attention to resource inputs and health outcomes, and
prudent use of technology are all significant lessons the
US must incorporate to deliver equitable, high-quality
health care to the whole population.
Aside from the knowledge-generating benefits, invest-
ing in health and development has powerful economic
and social returns. Direct economic benefits described by
the UN Secretary General at a Forum on Global Health
recently include six-fold economic returns on investments
in basic health services; from the US$1.5 billion in
treatment costs saved by governments annually through
Polio eradication campaigns in sub-saharan Africa, to
the US$27 in health expenses saved per dollar invested in
vaccines in the US (27). Healthy people incur less health
expenses, suffer less morbidity, and generate more
productivity.
Finally, while the US’ image worldwide may have
suffered due to foreign, economic, and trade policies of
previous administrations, it did receive appreciation and
adulation for its contributions to human welfare and
education development. In particular, the President’s
Emergency Plan for AIDS Relief has had a profoundly
positive effect, exemplifying greater goodwill and influ-
ence (soft power) that can be gained from addressing the
compelling and influential humanitarian imperative of
health in LMICs. The IOM’s advocacy for more invest-
ment in global health research and programs can there-
fore improve the country’s image further, distinguishing
itself as a responsible steward of health and peace.
Implications
Contemporary globalization, characterized by rapid
growth of technology, digital communication, migration,
and large emerging markets, is quickly creating an
interdependent world, but also shapes population health.
Transitioning demographic, nutritional, and lifestyle
patterns that accompany these developments result in
changing epidemiological patterns. Ageing, global warm-
ing, marketization, adoption of sedentary lifestyles and
calorie-dense low-fiber diets, and changing modes of
transport between and within countries, together result in
increasingly common health challenges (obesity, diabetes,
and escalating costs of health care) as well as rapid
transmission of health threats and information across
countries. The imperative for coordination and invest-
ment in health is paramount given the mounting burdens
of chronic NCDs and looming issues of climate change.
As such, the IOM report sets out progressive recommen-
dations, but what of the adoption of these proposed
schemes, and what metrics need to be considered to
adequately evaluate these?
The emergence of the Brazil, Russia, India, and China
(BRIC) economies signals an era of changing social,
political, and economic forces worldwide. The combined
economies of these four countries are expected to be
larger than the G6 within 40 years (28). Additionally, the
ever-increasing speed and access to information technol-
ogy will yield increasingly aware populations, cognizant
of current affairs worldwide. In this changing world, the
US will need to adapt to maintain its historical interna-
tional competitiveness. The cited examples (16, 20, 25,
26) of research, cheaper manufacturing, care delivery,
and regulation offer glimpses of innovation born out of
need, in different settings where resource inputs and
market size plus composition vary. As such, global
health offers areas of great need for investment in
innovation and education.
We recognize that several challenges will need to be
addressed, including lack of infrastructure and standar-
dized quality assurance, competing agendas, and differ-
ences in the politics and culture of scientific research
across countries. Can these barriers and global health
challenges truly be overcome without cooperation from
the other influential countries worldwide? Also, could one
legitimately expect collaboration from these ‘Group of 20’
countries, given the current economic conditions world-
wide and the associated competing priorities? Political
esteem is currently intimately linked with domestic public
sentiment leading to legitimate prioritization of their own
citizens’ concerns, domestic politics, and protectionism.
Free market and trade liberalization ideologies have been
‘modified’ by wealthier nations to exploit large consumer
markets overseas while regulating imports of competitive
products from these countries; this will ensure that the
equity gap between wealthier nations and LMICs will be
maintained, no matter how noble the country’s perspec-
tive. Amidst these issues, is it realistic for us to believe
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enough on the agenda of high-income countries unless
consumer market size is threatened?
It must also be recognized that if a greater proportion
of financial investment is committed by wealthier nations,
this strongly influences the nature of the relationship with
their counterparts in LMICs, whereby the ‘equal’ and
‘respectful’ partnership remains a mere fac ¸ade. Other
limiting factors of this report are the lack of actual,
specific steps toward engaging US politicians, academics,
and citizens in the realm of global health; the relative
contributions of these various groups in their respective
roles; building and implementing partnerships; and
evaluating the outcomes. Lastly, while the report reflects
on the strengths and past successes of US institutions
(such as the NIH, USAID, CDC, and academia) globally,
it does not detail the transformation and adaptations
required to reframe their global engagement to align with
the report’s recommendations.
Wider translation of available knowledge and technol-
ogies into health practice and policy globally must
contend with a complex mix and different levels of
challenges, and will probably require collective commit-
ments from a number of wealthy nations. Even though
the equitygap is large, and the process of addressing these
issues looms lengthy and arduous, we cannot ignore our
commitment to global health. In the words of Martin
Luther King, ‘Injustice anywhere is a threat to justice
everywhere.’ In much the same way, in today’s world,
poor health anywhere is a threat to good health every-
where.
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